Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data

CNS Neuroscience and Therapeutics

Volumn 17, Issue 5, 2011, Pages 428-441

  Van Laar, Teus ^a   De Deyn, Peter Paul ^b   Aarsland, Dag ^c,d   Barone, Paolo ^e   Galvin, James E ^f  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d AHUS University Hospital   (Norway)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholinesterase inhibitors; Donepezil; Parkinson's disease dementia; Review; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; TACRINE;

COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; NAUSEA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; VOMITING;

ANIMALS; CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80053217764     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00166.x     Document Type: Review

References (78)

1. Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-376.
2. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology 2007;68:326-337.
3. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 2006;67:1605-1611.
4. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002;51:722-729.
5. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255-1263.
6. Buter TC, Van Den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: A 12-year population study. Neurology 2008;70:1017-1022.
7. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2009;289:18-22.
8. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: Similarities and differences. J Alzheimers Dis 2007;11:509-519.
9. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.
10. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17:137-145.
11. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536.
12. Lauterbach EC. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am 2004;27:801-825.
13. Galvin JE. Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 2006;20:302-310.
14. Kitayama M, Wada-Isoe K, Nakaso K, Irizawa Y, Nakashima K. Clinical evaluation of Parkinson's disease dementia: Association with aging and visual hallucination. Acta Neurol Scand 2007;116:190-195.
15. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.
16. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: A retrospective autopsy study. Lancet Neurol 2005;4:605-610.
17. Huber SJ, Paulson GW, Shuttleworth EC. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:855-858.
18. Reid WG, Hely MA, Morris JG, Broe GA, Adena M, Sullivan DJ, Williamson PM. A longitudinal of Parkinson's disease: Clinical and neuropsychological correlates of dementia. J Clin Neurosci 1996;3:327-333.
19. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112-1118.
20. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866-874.
21. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
22. Braak H, Griffing K, Braak E. Neuroanatomy of Alzheimer's disease. Alz Res 1997;3:235-247.
23. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
24. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
25. Hornykiewicz O. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: The view of an eyewitness. Neurodegener Dis 2008;5:114-117.
26. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413-421.
27. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7:69-79.
28. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-1748.
29. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:324-325.
30. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
31. th International Conference on Alzheimer's and Parkinson's Diseases, Salzburg, Austria, 2007.
32. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164-171.
33. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006.doi: .
34. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.
35. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-939.
36. Poewe W, Wolters E, Emre M, et al; EXPRESS Investigators. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. Mov Disord 2006;21:456-461.
37. Dujardin K, Devos D, Duhem S, et al. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. J Neurol 2006;253:1154-1159.
38. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series. Curr Med Res Opin 2002;18:258-264.
39. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002;23:41-43.
40. Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003;16:184-188.
41. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord 2001;16:1171-1174.
42. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
43. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
44. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
45. Fahn S, Elton R; Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park, NJ MacMillan Healthcare Information, 1987;153-164.
46. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
47. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:988-993.
48. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005;20:938-944.
49. Muller T, Welnic J, Fuchs G, Baas H, Ebersbach G, Reichmann H. The DONPAD-study: Treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl 2006;71:27-30.
50. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002;25:107-110.
51. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-941.
52. Litvinenko IV, Odinak MM, Mogil'naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol 2008;38:937-945.
53. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003;108:368-373.
54. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
55. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: Overview and research. J Neural Transm Suppl 1993;39:165-172.
56. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC American Psychiatric Association, 1994.
57. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S22-S32.
58. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-S39.
59. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: A validation study. Int J Geriatr Psychiatry 1991;6:95-102.
60. Delis D, Kaplan E, Kramer J. Delis-Kaplan executive function system. San Antonio, TX Psychological Corporation, 2001.
61. Manos PJ, Wu R. The ten point clock test: A quick screen and grading method for cognitive impairment in medical and surgical patients. Int J Psychiatry Med 1994;24:229-244.
62. Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: A retrospective analysis of a double-blind trial and an open-label extension. Drug Saf 2008;31:79-94.
63. Ballard C, Lane R, Barone P, Ferrara R, Tekin S. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006;60:639-645.
64. Rowan E, McKeith IG, Saxby BK, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2007;23:161-167.
65. Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 2001;108:1319-1325.
66. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654-1656.
67. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907.
68. Schretlen D, Bobholz JH, Brandt J. Development and psychometric properties of the brief test of attention. Clin Neuropsychol 1996;10:80-89.
69. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. Am J Occup Ther 1999;53:471-481.
70. Harvey PD, Ferris SH, Cummings JL, Wesnes KA, Hsu C, Lane RM, Tekin S. Evaluation of dementia rating scales in Parkinson's disease dementia. Am J Alzheimers Dis Other Demen 2010;25:142-148.
71. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
72. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease: Rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-467.
73. Bullock R, Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007;4:277-293.
74. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: Epidemiology and treatment recommendations. Drugs Aging 2000;17:363-384.
75. Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: Implications of recent safety warnings. Curr Med Res Opin 2005;21:1-10.
76. Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, Perry RH. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990;55:1454-1456.
77. Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM. Rivastigmine versus placebo in hyperhomo-cysteinemic Parkinson's disease dementia patients. Mov Disord 2008;23:1532-1540.
78. Ferris S, Nordberg A, Soininen H, Darreh-Shori T, Lane R. Progression from mild cognitive impairment to Alzheimer's disease: Effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet Genomics 2009;19:635-646.